| Abstract |
Eribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC) chemotherapy in late lines by the FDA, with debated results in 2nd line. We evaluated outcomes in breast cancer patients receiving EM as second, third and fourth line in a national real-life cohort of 16,703 consecutive MBC patients initiating their first metastatic therapeutic line between 2008 and 2014. Primary and secondary objectives were overall survival (OS) and progression-free (PFS). An imbalance was seen for HER2+ tumors and concomitant anti-HER2 targeted therapies use, we thus performed a sub-analysis in HER2- patients. PFS and OS were significantly better in EM patients in 3rd and 4th lines, compared to "Other chemotherapies" patients (PFS: 4.14 vs. 3.02 months, p=0.0010; 3.61 vs. 2.53 months, p=0.0102, 3rd and 4th -line; OS: 11.27 vs. 7.65 months, p=0.0001; 10.91 vs. 5.95 months, p<0.0001, 3rd and 4th -line). No significant difference was reported in 2nd -line (PFS: 5.06 vs. 4.14 months, p=0.1171; OS: 13.99 vs. 11.66 months, p=0.151). Among HER2- patients, a significant difference was seen for all lines, including 2nd -line (PFS: 4.57 vs. 3.91 months, p=0.0379; OS: 14.98 vs. 10.51 months, p=0.0113). In this large real-world database, HER2-negative MBC patients receiving EM in 2nd or later chemotherapy line presented significantly better PFS and OS. This difference disappeared in 2nd line in the overall population, probably because of the imbalance in HER2-targeted treatments use. Our results mirror those of the published randomized trials. The effect of anti-HER2 therapies addition in this setting still needs to be defined. This article is protected by copyright. All rights reserved. |
Institut de Recherche en Cancérologie de
